Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Cleanroom Design for Pharmaceutical GMP Compliance in 2026

GMP inspections frequently identify facility and environmental control weaknesses as root causes of compliance risk. This article examines how cleanroom standards, layout decisions, and documentation influence contamination control, inspection readiness, and regulatory expectations across pharmaceutical manufacturing environments.
  • Blog, GMP, GxP, Quality Management System
Pharmaceutical cleanroom layout showing ISO cleanroom classification, airflow and pressure cascade, and contamination control strategy aligned with GMP cleanroom design requirements.

EMA Nitrosamine Requirements and Appendix 1 Inspection Focus in 2026

EMA nitrosamine Appendix 1 has reshaped how inspectors assess risk, justification, and lifecycle oversight. This article explains what regulators review during GMP inspections, how expectations apply in practice, and why governance gaps often escalate nitrosamine-related findings.
  • Blog, Nitrosamine
QA and regulatory team discussing EU GMP nitrosamine control strategy and regulatory expectations during inspection readiness review.

Qualification vs Validation: inspection perspective in 2026

This article examines how inspectors distinguish qualification from validation during GMP reviews. It focuses on equipment qualification GMP, process validation GMP, and lifecycle governance, showing how clear alignment across activities strengthens inspection readiness and reduces repeat compliance findings.
  • Blog, Validation and Qualification
Pharmaceutical QA and validation team discussing qualification and validation activities to support validation lifecycle approach and audit readiness validation systems

Validation master plan (VMP): inspection expectations in 2026

This article explains how validation governance supports inspection readiness by aligning validation strategy, GMP documentation, and lifecycle oversight. It focuses on inspection expectations, decision traceability, and how pharmaceutical manufacturers use structured validation planning to reduce audit risk.
  • Blog, Validation and Qualification
GMP validation documentation and validation lifecycle approach supporting inspection readiness and audit evidence in pharmaceutical manufacturing.

“Biofilm Doesn’t Grow Overnight — It Grows on Weak Monitoring” Microbial Contamination & Biofilm Formation in PW Systems

Purified Water systems seldom fail due to equipment; they decline silently through biofilm formation, flawed loop design, and absent microbial trending. In a project at a South American pharmaceutical company we found significant microbial deviations with no investigations or trending
  • Blog
Evaluating existing batch record review processes to enhance compliance, accuracy, and process efficiency.

Your PW Validation Is Built on Guesswork — And That’s Why It’s Failing

During a PW validation for a South American pharma manufacturer, the team found solid equipment but no meaningful risk assessment. Parameters were adopted without justification and worst-case conditions were not challenged. Validations were paperwork-only, leading to rework, inspection findings, delays,
  • Blog
Training session for internal audit teams, focusing on audit techniques and documentation best practices.

A Validated System Can Still Fail — If You Don’t Review It

A Pharma company’s purified water (PW) system remained officially validated, but after three years without reassessment or maintenance it drifted out of its validated state. Lack of periodic requalification, preventive maintenance, and trending led to unpredictable performance and increased risk
  • Blog
Consultant inputting Nitrosamines data into risk assessment tool.

Your CSV Timeline Isn’t Failing Because of LIMS — It’s Failing Because People Won’t Follow the Template

During a LabWare LIMS 8.0 implementation at a Japanese pharma site, validation was delayed not by the system but by users modifying approved Excel test templates. Despite training and procedures, changes to formatting, formulas, and columns prevented uploads to ALM,
  • Blog

Your CSV Process Is Failing — Not Because of Technology, But Because Your QMS Is Weak

Zamann Pharma Support found that CSV failures often stem not from technical issues but from weak Quality Management Systems. At a German site, gaps in QA structure, SOPs, training, and IT governance undermined validation efforts. Without defined ownership, integrated SOPs,
  • Blog

One Plant, Two Worlds: How Mixed Digital Maturity Sabotages Your GMP Teams

Many facilities run modern digital lines alongside paper-based ones, forcing experts to work across two incompatible systems. This creates hidden costs, delays in investigations, training burdens, and increased data integrity risk. The article outlines where misalignment appears and offers a
  • Blog
Consultant inputting Nitrosamines data into risk assessment tool.